Achieve Life Sciences (ACHV) Total Non-Current Liabilities (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Total Non-Current Liabilities came in at $21.2 million in Q1 2026, up 33.56% YoY from $15.8 million in Q1 2025, and up 13.04% on a QoQ basis from $18.7 million in Q4 2025.
Achieve Life Sciences (ACHV) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 12 years of Total Non-Current Liabilities data on file, last reported at $21.2 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 33.56% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 33.56% YoY) and the FY2025 annual result came in at $18.7 million, up 12.84% from the prior year.
- Total Non-Current Liabilities advanced to $21.2 million in Q1 2026, from $18.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $21.9 million in Q2 2024 to a low of $15.8 million in Q1 2025.
- A 4-year average of $18.6 million and a median of $18.6 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities decreased 21.04% — and 2026, when it jumped 33.56%.
- Tracing ACHV's Total Non-Current Liabilities over 4 years: stood at $20.3 million in 2023, then retreated by 18.26% to $16.6 million in 2024, then increased by 12.84% to $18.7 million in 2025, then grew by 13.04% to $21.2 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $21.2 million (Q1 2026), $18.7 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 22.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.39 Mn |
| Mar 31, 2026 | 21.16 Mn |
| Dec 31, 2025 | 18.72 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Jun 30, 2025 | 17.27 Mn |
| Mar 31, 2025 | 15.84 Mn |
| Dec 31, 2024 | 16.59 Mn |
| Sep 30, 2024 | 15.84 Mn |
| Jun 30, 2024 | 21.87 Mn |
| Mar 31, 2024 | 19.99 Mn |
| Dec 31, 2023 | 20.29 Mn |
| Sep 30, 2017 | 2.34 Mn |
| Jun 30, 2017 | 1.66 Mn |
| Mar 31, 2017 | 1.83 Mn |
| Dec 31, 2016 | 2.97 Mn |
| Sep 30, 2016 | 10.31 Mn |
| Jun 30, 2016 | 12.98 Mn |
| Mar 31, 2016 | 14.19 Mn |
| Dec 31, 2015 | 19.66 Mn |
| Sep 30, 2015 | 26.63 Mn |